Talquetamab (Talvey®). HTA ID: 23057

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23057
Drug Talquetamab
Brand Talvey®
Indication Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 20/09/2023
Rapid review completed 10/11/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talquetamab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/11/2023
Pre-submission consultation with Applicant 23/01/2024